Direct AI-Based Medical X-Ray Imaging System a Paradigm-Shift from Conventional DR and CT

A groundbreaking intelligent tomosynthesis X-ray imaging system aims to seamlessly blend the capabilities of digital radiography (DR), computerized tomography (CT), and the expertise of a seasoned radiologist in one smart package. This integrated system could deliver accountable and consistent diagnostic reports within seconds of scanning the patient.

AIxSCAN, Inc. (Sunnyvale, CA, USA) is introducing ARC60, an AI-based tomosynthesis X-ray imaging system that combines the functionalities of DR, CT, and an experienced radiologist into a single package. This direct AI-based medical X-ray imaging system, which marks a paradigm shift from conventional DR and CT, aims to enable accurate diagnoses and tracking of abnormalities over time. This technology will allow the radiologist to complete a scan, assist the physician in providing a diagnosis, and create a report efficiently and at a low radiation dose (from 1/20 to 1/40 that of a typical CT).

Image: AIxScan leverages cutting-edge AI and hardware advancements to redefine X-ray imaging (Photo courtesy of AIxSCAN)

AIxScan leverages cutting-edge AI and hardware advancements to redefine X-ray imaging. By optimizing algorithms, the ARC60 system achieves short screening times, large-angle imaging, and ultra-high resolution, resulting in quick and accurate diagnostics. The integration of AI-driven dose optimization improves safety with ultra-low-dose X-ray exposure, while a standalone unit with high mobility, combined with cost-effective acquisition and ownership, marks a groundbreaking shift, making advanced medical imaging more affordable and accurate. The early ARC60 imaging results from clinical trials that began in late 2023 have been encouraging, both in terms of depiction of details and consistency of imaging quality. Between late 2023 and early 2024, AIxSCAN plans to produce over 50 lung disease patient scans in the U.S. and up to 1,000 total lung disease patient scans within two years. The company will use some of the data to support its 510k submission to the FDA in 2024.

“This innovative technology has the potential to change the way we diagnose a range of medical conditions,” said Norbert Pelc, Sc.D., Professor of Radiology, Emeritus at Stanford University and AIxSCAN Advisory Board member. “The AIxSCAN tomosynthesis X-ray scanner does not completely avoid the superimposition limitations of radiography, but the early results from the prototype system are very encouraging and suggest the technology can play a significant role. I believe that AIxSCAN's tomosynthesis X-ray scanner has a very good chance of becoming a valuable tool for the medical community. This technology has the potential to improve patient care and save lives.”